News & Blog

NBTS Brain Tumor Clinical Trials Report: Q2 2021

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the party responsible for enrolling patients, just follow the hyperlink.**

  • Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
    • In this phase II study, safety, response to treatment, and progression-free and overall survival will be evaluated for the drug ivosidenib in combination with nivolumab in patients with advanced solid tumors (unresectable or metastatic) or enhancing gliomas.
  • A Pilot Study of Larotectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion 
    • This is a pilot study (early phase I trial) called “CONNECT1903” that will evaluate disease status in children that have been newly diagnosed with high-grade glioma with TRK fusions. The evaluation will occur after 2 cycles of the medication larotrectinib have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy as well as the safety of larotrectinib when given post-focal radiation therapy.
    • This phase I/II trial studies the effect of the investigational drug NGM707 alone and in combination with the immunotherapy pembrolizumab for patients with advanced or metastatic solid tumor malignancies, including glioblastoma.
  • Surgical Resection of Latent Brain Tumors Prior to Recurrence
    • This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence) and to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.

Below is a list of phase III clinical trials that are currently enrolling patients as recorded at the close of 2020. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medicine before it is approved for use by all patients with the indicated disease.

Many of these are trials of a “novel/investigational agent” – meaning it is the first time a particular treatment is being tried for brain tumor patients. There are also a number of trials with therapies already in use for some brain tumor patients, for which researchers are evaluating these existing treatments in different combinations, different dosing regimens, and/or specific subgroups of patients.

Phase III Clinical Trials with Novel/Investigational Agents

Phase III Clinical Trials with Prior/Known Agents

*For a comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at, where you can search potential opportunities for enrollment based on criteria specific to you.

**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing Our patient navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse. Learn more here.

Post a Comment

Your email is kept private. Required fields are marked *